In Brief: Transkaryotic Therapies
Executive Summary
Transkaryotic Therapies: Initial public offering would consist of 2.5 mil. shares at $13-$15 per share, Cambridge, Mass.-based Transkaryotic announces Aug. 27. Morgan Stanley, UBS Securities and Pacific Growth Equities will underwrite the IPO. Transkaryotic has "two proprietary technology platforms," the company says: gene activation and a non-viral, ex vivo gene therapy system. Clinical trials of gene-activated erythropoietin are scheduled to begin in the first half of 1997 under a collaboration with Hoechst Marion Roussel...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth